Show simple item record

dc.contributor.authorWigina, Ronald Nyarambe
dc.contributor.authorJeza, Victor Tunje
dc.date.accessioned2024-02-21T10:00:53Z
dc.date.available2024-02-21T10:00:53Z
dc.date.issued2015-09
dc.identifier.citationJeza, V. T. MHC-Ig Dimers: The next Frontier in Transplantation Immunology?.en_US
dc.identifier.issn0976-9633
dc.identifier.urihttp://ir.tum.ac.ke/handle/123456789/17451
dc.descriptionDOI:10.7439/ijbr.v6i9.2327en_US
dc.description.abstractOrgan transplantation offers hope to a variety of patients with terminal functioning organs and tissues. This is currently made possible by administration of general immunosuppressive drugs. To date, inducing tolerance to allografts has become the holy grail of every transplantation immunologist. In effect, there has been a great deal of research aiming to come up with alternative therapeutic mechanisms that would allow one to do away with or reduce the amount of general immunosuppressive drugs used either at the induction, maintenance, or both phases. It has been shown in recent years that MHC-Ig dimers can induce suppression of alloresponsive T cells in a donor specific fashion. Consequently, MHC-Ig fusion proteins are currently forming the next field for exploitation which is great progress in transplantation immunology since the discovery of the first immunosuppressive drugs in terms of inducing tolerance to transplanted organs and tissues. This review aims to discuss this progress.en_US
dc.description.sponsorshipTECHNICAL UNIVERSITY OF MOMBASAen_US
dc.language.isoenen_US
dc.publisherInternational Journal of Biomedical Researchen_US
dc.subjectMHC-Ig dimeren_US
dc.subjectimmunosuppressive drugsen_US
dc.subjectgraft rejectionen_US
dc.subjecttransplant toleranceen_US
dc.titleMHC-Ig Dimers: The next Frontier in Transplantation Immunologyen_US
dc.typeArticleen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record